Bispecific molecules redirecting the cytotoxicity of T-cells are a growing class of therapeutics
with numerous molecules being tested in clinical trials. However, it has been a long way …

The advances in genetics and biochemistry that have taken place over the last 10 years led
to significant advances in experimental and clinical immunology. In turn, this has led to the …

Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and
immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) …

Adoptive T cell therapies have achieved significant clinical responses, especially in
hematopoietic cancers. Two types of receptor systems have been used to redirect the activity …

T cells use their T cell receptors (TCRs) to discriminate between lower-affinity self and
higher-affinity non-self peptides presented on major histocompatibility complex (pMHC) …

T cell activation is a crucial checkpoint in adaptive immunity, and this activation depends on
the binding parameters that govern the interactions between T cell receptors (TCRs) and …

T cells use their T‐cell receptors (TCRs) to discriminate between lower‐affinity self and
higher‐affinity foreign peptide major‐histocompatibility‐complexes (pMHCs) based on the …

In the thymus, high-affinity, self-reactive thymocytes are eliminated from the pool of
develo** T cells, generating central tolerance. Here, we investigate how develo** T …

The immune system distinguishes between self and foreign antigens. The kinetic
proofreading (KPR) model proposes that T cells discriminate self from foreign ligands by the …

Chimeric antigen receptors (CARs) can redirect T cells to target abnormal cells, but their
activity is limited by a profound defect in antigen sensitivity, the source of which remains …